

CSL Limited

CSL.AX | Healthcare | Biotechnology

KEY METRICS

Price	Mkt Cap	Fwd P/E	EV/EBITDA
A\$153.27	A\$138.5B	Pending	Pending
52wk Range	Div Yield	Revenue	NPAT
Pending	Pending	Pending	Pending

OVERALL SENTIMENT

Overall Sentiment	-16 DOWNSIDE
External Environment	+1
Company Research	-17

KEY TAKEAWAYS

- CSL continues doing what it does best — growing earnings at 7-10% per year, driven by its dominant position in the global plasma market. The company deserves its premium valuation because of its deep competitive...
- If growth slips below high single digits, the premium valuation may not be sustainable.
- External environment is neutral (score: +1). Macro and sector contributions are incorporated in the three-layer sentiment model.

Marc Duncan | DH Capital Partners
marc@dhcapital.com.au
21 February 2026 | Sydney

COMPANY OVERVIEW

CSL is a global biotech leader specialising in plasma-derived therapies and vaccines. It is one of only three companies worldwide that can collect and process blood plasma at scale, giving it an extremely strong competitive position.

NARRATIVE ASSESSMENT

CSL is a global biotech leader specialising in plasma-derived therapies and vaccines. It is one of only three companies worldwide that can collect and process blood plasma at scale, giving it an extremely strong competitive position.

MARKET CONTEXT

Macro Environment: NEUTRAL (external signal: +1)

Indicator	Value	Change
ASX 200	9,101.3	+3.2% 1mo
AUD/USD	0.7066	-0.8% 5d
RBA Cash Rate	4.10%	cutting gradually
VIX	19.6	

SECTOR CONTEXT

Model: HEALTHCARE PHARMA BIOTECH | Sector signal: +0 (company dominant)

COMPETING HYPOTHESES

Dominant Narrative: T2: Execution Risk in Transformation (survival probability: 55%)

T2: Execution Risk in Transformation [DOMINANT]

55%

CSL continues doing what it does best — growing earnings at 7-10% per year, driven by its dominant position in the global plasma market. The company deserves its premium valuation because of its deep competitive moat and long runway of growth.

Watch: FY26 earnings guidance at H1 result. If guidance stays at 7-10% NPATA growth, the base case holds firm.

Supporting evidence:

- Earnings Report: FY25 NPATA \$3.2B in-line; FY26 guidance 7-10% growth (conservative)
- Operational Data: Plasma collections +15% YoY; cost per litre declining but above pre-COVID levels
- Operational Data: Vifor synergies tracking to \$200M target; iron portfolio growing 12% organically

T1: Structural Compounder Resumes

45%

CSL's plasma collection business is recovering from COVID disruption, and its recent acquisition of Vifor Pharma is starting to deliver cost savings. If both trends continue, earnings growth could accelerate beyond current expectations.

Watch: H1 FY26 plasma collection volumes and Vifor integration milestones. If plasma cost per litre returns to pre-COVID levels, this narrative strengthens significantly.

Supporting evidence:

- Operational Data: Plasma collections +15% YoY; cost per litre declining but above pre-COVID levels
- Operational Data: Vifor synergies tracking to \$200M target; iron portfolio growing 12% organically

T3: Structural Headwinds Emerging

40%

Several things could go wrong at once: the Vifor acquisition might cost more to integrate than expected, plasma margins might not recover as fast as management promised, and the strong Australian dollar could eat into overseas earnings when converted back.

Watch: Vifor integration costs in H1 FY26 and AUD/USD exchange rate trajectory. If integration costs rise or AUD strengthens above 0.70, downside risk increases.

Contradicting evidence:

- Earnings Report: FY25 NPATA \$3.2B in-line; FY26 guidance 7-10% growth (conservative)

T4: M&A or Corporate Event

35%

This is the long-term existential risk: if gene therapy advances make immunoglobulin treatments unnecessary, or if biosimilar competitors undercut CSL's key products, the company's core business could face structural decline.

Watch: Gene therapy clinical trial results targeting primary immunodeficiency conditions, and any biosimilar approvals for immunoglobulin products in major markets.

Contradicting evidence:

- Earnings Report: FY25 NPATA \$3.2B in-line; FY26 guidance 7-10% growth (conservative)

DIAGNOSTIC EVIDENCE

The following evidence items have the highest discriminating power between hypotheses:

Evidence Item	T2	T1	T3	T4	Diagnosticity
FY25 NPATA \$3.2B in-line; FY26 guidance 7-10% growth (conservative)	C	N	I	I	HIGH
Garadacimab Phase III positive for hereditary angioedema prevention; regulatory submission...	N	C	I	I	HIGH
Plasma collections +15% YoY; cost per litre declining but above...	C	C	I	N	MEDIUM
Vifor synergies tracking to \$200M target; iron portfolio growing 12%...	C	C	I	N	MEDIUM

C = Consistent, I = Inconsistent, N = Neutral. Diagnosticity = ability to discriminate between hypotheses. HIGH/CRITICAL items are most informative.

KEY DISCRIMINATORS

The following high-diagnosticity evidence items are most informative for discriminating between hypotheses:

- FY25 NPATA \$3.2B in-line; FY26 guidance 7-10% growth (conservative) (Supports: T2; Contradicts: T3, T4)
- Garadacimab Phase III positive for hereditary angioedema prevention; regulatory submission planned (Supports: T1; Contradicts: T3, T4)

TRIPWIRES

Condition	Trigger	Action
FY26 earnings guidance at H1 result. If guidance stays at 7-10% NPATA...	Per hypothesis thresholds	Reassess T2 narrative
H1 FY26 plasma collection volumes and Vifor integration milestones. If plasma cost...	Per hypothesis thresholds	Reassess T1 narrative
Vifor integration costs in H1 FY26 and AUD/USD exchange rate trajectory. If...	Per hypothesis thresholds	Reassess T3 narrative

TECHNICAL PICTURE

Technical analysis pending - signals will be incorporated when the TA agent is deployed.

ANALYTICAL GAPS

The following information would materially improve the confidence of this analysis:

- Management guidance on forward P/E and revenue trajectory - required to validate Growth/Recovery hypothesis.
 - Independent market share data - needed to assess competitive dynamics and test downside scenarios.
 - Balance sheet composition and net debt position - required to stress-test valuation under rate scenarios.
 - Analyst consensus estimates and revision trends - to calibrate sentiment score against market positioning.
 - Customer cohort data or NPS trends - to validate operational execution claims in company guidance.
-

UPCOMING CATALYSTS

Catalyst calendar pending. Key items to monitor:

- Last narrative event: 2025-08-20 - FY25 result in-line but guidance conservative; plasma margin recovery on track but gradual
- Next results date: Pending (monitor ASX announcements)
- Monitor hypothesis tripwires for narrative-change signals.

IMPORTANT INFORMATION

This document is prepared by DH Capital Partners Pty Ltd for informational purposes only. It does not constitute financial advice, a recommendation, or an offer to buy or sell any securities.

METHODOLOGY

This analysis uses the Analysis of Competing Hypotheses (ACH) framework, originally developed by Richards Heuer at the CIA for intelligence analysis and adapted here for equity research. ACH evaluates multiple competing explanations against diagnostic evidence, ranking hypotheses by the fewest inconsistencies rather than the most confirmations. This approach is designed to reduce confirmation bias and anchoring effects common in traditional equity research.

Sentiment scores are generated by a three-layer decomposition model separating macro environment, sector/commodity factors, and company-specific research. The 40/60 rule ensures company-specific research always contributes at least 60% of the overall sentiment, maintaining focus on idiosyncratic stock drivers.

LIMITATIONS

- Hypothesis scores are model outputs, not price targets or investment recommendations.
- Evidence assessment involves subjective judgement and may contain errors.
- Past price performance is not indicative of future returns.
- This analysis does not account for individual investor circumstances, risk tolerance, or tax position.
- Data sources include ASX announcements, broker research, company filings, and market data. Errors in source data will propagate.

CONFLICTS

DH Capital Partners and/or its principals may hold positions in securities discussed in this document. Positions may change without notice.

CONTACT

Marc Duncan

DH Capital Partners

marc@dhcapital.com.au

Sydney, Australia

(c) 2026 DH Capital Partners Pty Ltd. All rights reserved.